JP2018518537A5 - - Google Patents

Info

Publication number

JP2018518537A5

JP2018518537A5 JP2018517671A JP2018517671A JP2018518537A5 JP 2018518537 A5 JP2018518537 A5 JP 2018518537A5 JP 2018517671 A JP2018517671 A JP 2018517671A JP 2018517671 A JP2018517671 A JP 2018517671A JP 2018518537 A5 JP2018518537 A5 JP 2018518537A5

Authority

JP

Japan

Prior art keywords

compound according

item

compound

pharmaceutically acceptable

solvate

Prior art date

2016-06-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 59
• 150000002148 esters Chemical class 0.000 claims description 8
• 150000003839 salts Chemical class 0.000 claims description 8
• 239000012453 solvate Substances 0.000 claims description 8
• 230000002265 prevention Effects 0.000 claims description 7
• IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 claims description 6
• 102100025353 G-protein coupled bile acid receptor 1 Human genes 0.000 claims description 6
• 101000857733 Homo sapiens G-protein coupled bile acid receptor 1 Proteins 0.000 claims description 6
• 201000010099 disease Diseases 0.000 claims description 6
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
• 239000003814 drug Substances 0.000 claims description 6
• 229940079593 drug Drugs 0.000 claims description 6
• 238000004519 manufacturing process Methods 0.000 claims description 6
• 230000001404 mediated effect Effects 0.000 claims description 6
• 208000030159 metabolic disease Diseases 0.000 claims description 6
• 125000001715 oxadiazolyl group Chemical group 0.000 claims description 6
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
• 229910052799 carbon Inorganic materials 0.000 claims description 4
• 125000004432 carbon atom Chemical group C* 0.000 claims description 4
• 208000016097 disease of metabolism Diseases 0.000 claims description 3
• 125000000217 alkyl group Chemical group 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims 8
• XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 8
• 239000004471 Glycine Substances 0.000 claims 4
• 108010077895 Sarcosine Proteins 0.000 claims 4
• 229960002449 glycine Drugs 0.000 claims 4
• 229940043230 sarcosine Drugs 0.000 claims 4
• 229960003080 taurine Drugs 0.000 claims 4
• 239000000203 mixture Substances 0.000 claims 3
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
• 101100294103 Caenorhabditis elegans nhr-31 gene Proteins 0.000 claims 1
• 125000000547 substituted alkyl group Chemical group 0.000 claims 1
• -1 tautomer Chemical class 0.000 description 11
• 150000001413 amino acids Chemical class 0.000 description 4
• 239000002207 metabolite Substances 0.000 description 4
• 238000000034 method Methods 0.000 description 3
• OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2